Book Reviews | Gordon Campbell | News Flashes | Scoop Features | Scoop Video | Strange & Bizarre | Search

 


Hormone Therapy Makes Comeback--Are Cigarettes Next?

Hormone Therapy Makes Comeback--Are Cigarettes Next?

by Martha Rosenberg
November 9, 2012


Click for big version.

It has been almost ten years since a US government study found that hormone replacement therapy (HRT) did not prevent heart disease and memory loss as advertised but increased the risk of heart attacks by 29 percent and doubled the risk of dementia. Oops.

That was not all the bad news that emerged about HRT. It also increased the risk of breast cancer by 26 percent, stroke by 41 percent, doubled the risk of blood clots and increased the risk of hearing loss, gall bladder disease, urinary incontinence, asthma, the need for joint replacement, melanoma, ovarian, endometrial and lung cancers and non-Hodgkin's lymphoma, according to medical journals.

It was not exactly the fountain of youth it was billed as by hormone drug maker Wyeth (now Pfizer) in high-budget menopause awareness TV ads starring model Lauren Hutton.

In fact, HRT was such a scourge against women, in the first year that millions quit, 2003, the incidence of US breast cancer fell seven percent. It fell 15 percent among women whose tumors were fed by estrogen. Fourteen thousand women who were expected to get breast cancer didn't said news reports. And it wasn't just breast cancer women were spared: heart attack and ovarian cancer rates also fell when women quit HRT, said news reports.

The statistics must have been embarrassing to cancer researchers and public health officials. Not only was a major cause of breast cancer hidden in plain sight, the war on cancer should apparently have been a war on cancer-causing drugs!

It was even more embarrassing because the whole sequence happened before! In 1975, a Food and Drug Administration (FDA) panel found a link between Premarin (a Wyeth HRT drug) and endometrial cancer and when women quit the drug by the millions--the same thing happened. "There was a sharp downward trend in the incidence of endometrial cancer that paralleled a substantial reduction in prescriptions for replacement estrogens," reported the New England Journal of Medicine (NEJM) in 1979.

Not wanting to lose its billion dollar HRT franchise, Wyeth's medical director wrote doctors at the time that HRT still had "proven benefits" at the "the lowest maintenance dose" and that it was "simplistic indeed to attribute an apparent increase in the diagnosis of endometrial carcinoma solely to estrogen therapy."

Thirty years later, when cancer rates again dropped, Wyeth also bit back. It announced the reason women weren't seeing prevention of heart disease and memory loss from HRT was they weren't taking it soon enough. They needed to start treatment sooner. Ka-ching. The early treatment campaign was called the "timing theory."

Soon a National Institute on Aging trial and privately funded trials on "menopausal" primates, both led by Wyeth-funded investigators, were underway at major medical centers. After all, before 2002, millions of American women, perhaps the majority, had been on HRT. Wasn't there a way to get them back?

Last month the hormone revival campaign hit pay dirt. Women "who took treatments such as Pfizer Inc.'s estrogen pill Premarin within five years of menopause lowered their chance of Alzheimers by 30 percent," wrote the Washington Post about a study in the journal Neurology.

"It's really important to distinguish between studies that are able to look at early use of hormone therapy versus later use," said Pauline M. Maki, PhD on WebMD about the same study. Maki has received research support from Wyeth according to a July 2010 article in the journal Menopause. WebMD just imported a new CEO from Pfizer.

The study was funded by the National Institute on Aging (NIA) not Big Pharma. But NIA is so collegial with hormone makers, it funded the North American Menopause Society's entire 2009 annual meeting replete with Wyeth-funded doctor presenters and even Wyeth employee presenters. It also invited top Wyeth officials for a "Where Are We Now?" meeting soon after its products were linked to cancer/heart disease/blood clots/stroke/dementia.

Even if HRT did lower Alzheimer risk--would it be ethical to prescribe it in light of its other risks or even conduct trials? HRT's negative cognitive effects are so well known, a 2006 Reuters story began, "Regular exercise may prevent the mental decline associated with the long-term use of hormone replacement therapy (HRT)." And two studies in the January 13, 2009 issue of Neurology link HRT to brain shrinkage.

Hormone markers have also floated the idea that early HRT would prevent heart disease and/or cancer. But a 2011 analysis from the Million Women Study, sponsored by England's National Health Service, found women who took hormones the earliest, before or soon after the onset of menopause, were at the greatest risk of getting breast cancer.

Why does the government let--and even help--Big Pharma market HRT like it's a brand new product instead of the cause of two cancer epidemics--so far? Would anyone tell cigarette smokers to start smoking earlier?

*************

The complete story of unethical marketing of HRT to women is found in Martha Rosenberg's recent book, Born with a Junk Food Deficiency.

© Scoop Media

 
 
 
 
 
Top Scoops Headlines

 

David Swanson: Torture Is Mainstream Now

As Rebecca Gordon notes in her new book, Mainstreaming Torture, polls find greater support in the United States for torture now than when Bush was president. And it's not hard to see why that would be the case. More>>

Uri Avnery: In One Word: Poof!

Poor John Kerry. This week he emitted a sound that was more expressive than pages of diplomatic babble. In his testimony before the Senate Foreign Relations committee he explained how the actions of the Israeli government had torpedoed the “peace ... More>>

Binoy Kampmark: The Poverty Incentive: Making The Poor Carry The Refugee Can

The poorer you are, the more likely you need to shoulder more. This axiomatic rule of social intercourse, engagement and daily living is simple and brutal enough: the poor shall hold, conserve, preserve. More>>

Nureddin Sabir: BBC Misreports John Kerry On Talks Failure

For once, US Secretary of State John Kerry was not mincing his words when he blamed Israel for the breakdown of talks with the Palestinians. But you would not have known this if you were following the story from the BBC News website. More>>

Gordon Campbell: On Narendra Modi, And The Elections In India

On the upside, the gigantic election process that began yesterday in India is the largest exercise in democracy on the planet. Reportedly, a staggering five million people are employed, directly or indirectly, in the election process. The likely outcome is not quite so welcome... More>>

ALSO:

Ramzy Baroud: Kerry’s Looming Deadline And The Peace Process Industry

As the US-imposed April 29 deadline for a ‘framework’ agreement between the Israeli government and the Palestinian Authority looms, time is also running out for the American administration itself. More>>

Harvey Wasserman: Fighting Our Fossil-Nuke Extinction

The 25th anniversary of the Exxon Valdez disaster has brought critical new evidence that petro-pollution is destroying our global ecosystem. The third anniversary of the Fukushima Daiichi nuclear meltdown in Japan confirms that radioactive reactor ... More>>

Shobha Shukla: Rise In Global Health Financing, But Funding Priorities Shift

A new research done by the Institute for Health Metrics and Evaluation (IHME), at the University of Washington, indicates that globally the total development assistance for health (DAH) hit an all-time high of $31.3 billion in 2013 (a year-over-year ... More>>

Get More From Scoop

 
 
TEDxAuckland
 
 
 
 
Top Scoops
Search Scoop  
 
 
Powered by Vodafone
NZ independent news